BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15668194)

  • 1. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
    Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
    Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and comparative evaluation of a novel PAI-1 inhibitor.
    Gils A; Stassen JM; Nar H; Kley JT; Wienen W; Ries UJ; Declerck PJ
    Thromb Haemost; 2002 Jul; 88(1):137-43. PubMed ID: 12152654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
    Charlton PA; Faint RW; Bent F; Bryans J; Chicarelli-Robinson I; Mackie I; Machin S; Bevan P
    Thromb Haemost; 1996 May; 75(5):808-15. PubMed ID: 8725728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
    Lobov S; Croucher DR; Saunders DN; Ranson M
    Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
    Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.
    Rupin A; Gaertner R; Mennecier P; Richard I; Benoist A; De Nanteuil G; Verbeuren TJ
    Thromb Res; 2008; 122(2):265-70. PubMed ID: 18177924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
    Urano T; Wu K; Ihara H; Takada Y; Takada A
    Pol J Pharmacol; 1996; 48(2):209-13. PubMed ID: 9112653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
    Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
    J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.